Total amount raised
$1.5 Billions
Latest funding date
08/01/2023
Location
Biogen has participated in various funding rounds, with its most recent being a Post-IPO Debt round that closed on August 28, 2023. Among its notable investors is JP Morgan, which has shown significant backing for the company.
Keep reading to explore the intricacies of Biogen's fundraising journey and the investors supporting this biotechnology leader.
What Is Biogen?
Biogen, founded in 1978, is a pioneering biotechnology company based in Cambridge, Massachusetts. The company was established by Bernard Mach, Jeff Behrens, and Phillip Sharp.
Specializing in biotechnology, health care, neuroscience, and therapeutics, Biogen employs between 1001 and 5000 people. The company is renowned for its focus on developing treatments for neurological, autoimmune, and rare diseases.
As the world's oldest independent biotechnology company, Biogen is committed to scientific excellence and innovation, aiming to transform patient lives through its research and development efforts.
How Much Funding Has Biogen Raised?
- Funding Round Type: Post-IPO Debt
- Amount Raised: $1.5B
- Date: August 28, 2023
- Lead Investors: JP Morgan
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To finance Biogen's $7.3 billion acquisition of Reata Pharmaceuticals.
Total Amount Raised: $1.5B. Current Valuation: Not publicly disclosed.
Key Investors
The major investors in Biogen are as follows:
- JP Morgan
- Details: JP Morgan is a leading global financial services firm with operations worldwide. It provides investment banking, financial services for consumers and businesses, financial transaction processing, asset management, and private equity.
- Investment Focus Areas: Corporate finance, asset management, investment banking, commercial banking
- Notable Investments: Biogen, Amazon, Tesla
Note: The information requested about other major investors was not found in the provided sources.
What's Next for Biogen?
Biogen's acquisition of Reata Pharmaceuticals represents a significant opportunity to expand its portfolio and market reach. The $7.3 billion deal, financed through a $1.5 billion unsecured loan facility, positions Biogen to enhance its capabilities in treating neurological and rare diseases.
Future fundraising opportunities may arise as Biogen continues to seek strategic acquisitions to bolster its portfolio. However, integrating Reata Pharmaceuticals and managing the debt from the loan could present challenges. The biotechnology industry remains dynamic, and Biogen's ability to navigate these complexities will be crucial for its sustained growth.
Use Clay to Get Funding Data
Sales professionals looking to gain a competitive edge should leverage Clay’s platform to access comprehensive fundraising data on companies like Biogen and gather other critical business insights.
Sign up for free to start exploring the wealth of information available on Clay's platform and enhance your sales strategies today.
